19 related articles for article (PubMed ID: 9701209)
1. Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells.
Xiao Z; Wan J; Nur AA; Dou P; Mankin H; Liu T; Ouyang Z
Cell Physiol Biochem; 2018; 51(4):1879-1893. PubMed ID: 30504723
[TBL] [Abstract][Full Text] [Related]
2. Relation between cellular doxorubicin binding ability to nuclear DNA and histologic response to preoperative chemotherapy in patients with osteosarcoma.
Kusuzaki K; Takeshita H; Murata H; Hirata M; Hashiguchi S; Ashihara T; Hirasawa Y
Cancer; 1998 Jun; 82(12):2343-9. PubMed ID: 9635526
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?
Hattinger CM; Fanelli M; Tavanti E; Vella S; Riganti C; Picci P; Serra M
Future Oncol; 2017 Apr; 13(8):673-677. PubMed ID: 28183198
[No Abstract] [Full Text] [Related]
4. Assessment of chemosensitivity in patients with malignant bone and soft tissue tumors using thallium-201 scintigraphy and doxorubicin binding assay.
Murata H; Kusuzaki K; Takeshita H; Hirata M; Hashiguchi S; Emoto K; Ashihara T; Hirasawa Y
Anticancer Res; 2000; 20(5C):3967-70. PubMed ID: 11268485
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of P-glycoprotein immunohistochemistry and doxorubicin binding assay in patients with osteosarcoma.
Kumta SM; Zhu QS; Lee KM; Griffith J; Chow LT; Leung PC
Int Orthop; 2001; 25(5):279-82. PubMed ID: 11794258
[TBL] [Abstract][Full Text] [Related]
6. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines.
Luk F; Yu Y; Walsh WR; Yang JL
Cancer Invest; 2011 Oct; 29(8):521-32. PubMed ID: 21843050
[TBL] [Abstract][Full Text] [Related]
7. Assessment of chemosensitivity in patients with osteogenic sarcoma using the doxorubicin binding assay.
Kumta SM; Leung PC; Chow L; To SH; Lee S; Cheng SH
J Surg Oncol; 1998 Jul; 68(3):169-72. PubMed ID: 9701209
[TBL] [Abstract][Full Text] [Related]
8. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
9. Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.
Harrison DJ; Schwartz CL
Curr Treat Options Oncol; 2017 Apr; 18(4):24. PubMed ID: 28391422
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]